Genedata Licenses its Bioprocess Software Platform to Sartorius Stedim Cellca
First-in-class enterprise workflow platform for streamlining cell line development operations
Genedata, a leading provider of advanced software solutions for biopharma R&D, today announced that Sartorius Stedim Cellca GmbH, a subsidiary of Sartorius Stedim Biotech (SSB) and a specialist for cell line development and bioanalytical services for large-scale protein production, has licensed the Genedata Bioprocess® enterprise platform to be used at SSB laboratories in Germany, the U.K., the U.S., and South Korea. Genedata Bioprocess is expected to further increase effectiveness and experimental throughput of biotherapeutics CRO and CMO operations. “We aimed to extend automation and further enhance the efficiency of our cell line, upstream and bioanalytical development operations, and quickly realized that Genedata Bioprocess addresses many of our requirements off-the-shelf, eliminating the need for expensive customization. We therefore decided to implement Genedata Bioprocess across our development operations,” said Hugo de Wit, Managing Director at Sartorius Stedim Cellca and Sartorius Stedim BioOutsource. “We were also intrigued with the platform’s capability to be directly integrated into our wide array of laboratory equipment and with the way this would facilitate seamless transfer of data and samples along the full development workflow,” continued de Wit.
The enterprise platform will be used to manage diverse workflows and laboratory operations for the full Sartorius Stedim Cellca solution portfolio, helping its customers develop mAbs, Fc-fusion proteins, Fab-related products, bispecific antibodies, and biosimilars. In particular, the platform will support Sartorius Stedim Cellca’s unique cell line development process, consisting of proprietary expression vectors, host cell lines, CHO media systems and a tailored upstream process design. This will result in high yield, stable cell lines and robust, simple, easy-to-scale fed-batch processes, plus research cell banks (RCBs) and master cell banks (MCB). Customers stand to benefit from the efficiency of bioanalytical testing services provided by Sartorius Stedim Cellca and Sartorius Stedim BioOutsource based on simplified processes and even faster timelines.
“We are excited to collaborate with Sartorius Stedim Cellca, a leader in the CRO and CMO market for cell line and process development. Due to its global reach and excellent reputation, Sartorius Stedim Cellca is an ideal partner for Genedata,” said Dr. Othmar Pfannes, CEO of Genedata. “We strive to offer fully integrated solutions that reduce development time and costs, making both innovator drugs as well as biosimilars more affordable. We will continue to develop our biopharma platform to further automate and simplify bioprocess development operations.” The Genedata Bioprocess software solution enables fully integrated workflow management for large-molecule development and CMC operations. As an enterprise-wide data backbone, it supports the full E2E workflow – ranging from developing cell lines and upstream processes (USP) to downstream processes (DSP), as well as formulation and analytics. Genedata Bioprocess has been co-developed with major biopharmaceutical companies over the past five years.
Other news from the department business & finance
